Skip to main content
. Author manuscript; available in PMC: 2017 Jan 14.
Published in final edited form as: J Med Chem. 2015 Dec 30;59(1):219–237. doi: 10.1021/acs.jmedchem.5b01276

Figure 6.

Figure 6

(A) T47D:A18/PKCα tumors were established as described in the experimental section. Tumors were grown to an average size of 0.3 cm2. Mice were then randomized into three treatment groups: Ctrl (n = 4), 23 and 26a (n = 6). Administration of drug was by oral gavage daily (100 mg/kg). Within two weeks of treatment, a regression of established tumors was observed, while control tumors continued to grow. (B) Measured uterine weight (g) of Ctrl (n = 4) and 26a (n = 6) treatment groups showed no significant difference, suggesting an improved side effect profile. Data show mean and s.e.m.